Africa and Latin America: Named Instruments, Real Requirements

Part of Regulatory Affairs and the Jurisdiction Map: Jurisdictions with Their Own Instruments.

About 5 minutes. Free, in your language, no account needed.

Why this matters

There is a lazy way of talking about regulatory environments outside the traditional trial markets, and it is both inaccurate and commercially damaging. It treats whole regions as undifferentiated, assumes limited capability, and plans accordingly.

The verified record does not support that picture. The countries below have named statutory instruments, identified authorities, and in several cases formal international benchmarking. Two of them are ICH Regulatory Members, which is a higher participation category than several countries that would never be described this way.

Getting this right is not politeness. A sponsor that arrives with a generic dossier and an assumption of low expectations gets a slow review, and deserves one.

Nigeria

Nigeria is an ICH Regulatory Member. The authority is the National Agency for Food and Drug Administration and Control, operating under the NAFDAC Act, Cap F33 LFN 2004, section 5, with the Good Clinical Practice Regulations 2009 and the NAFDAC Good Clinical Practice Guidelines 2020.

NAFDAC is benchmarked at WHO maturity level 3 for medicines and vaccines as a non-producing country, assessed in 2026. Note the product scope: medicines and vaccines, which is broader than several of the other maturity level 3 designations in the register.

South Africa

South Africa is an ICH Regulatory Member. The authority is the South African Health Products Regulatory Authority, under the Medicines and Related Substances Act 101 of 1965, Regulation 30, with the South African Good Clinical Practice: Clinical Trial Guidelines, third edition 2020.

The register records that compliance with those guidelines is compulsory. That single word changes their status: guidance that is compulsory functions as regulation, and treating it as advisory is a category error.

SAHPRA is benchmarked at WHO maturity level 3 for vaccines as a producing country, assessed in 2022.

Kenya

Kenya is neither an ICH member nor an observer, and applies ICH E6(R3) as national guidance. The authority is the Pharmacy and Poisons Board, under the Pharmacy and Poisons Act, Cap 244, with the Pharmacy and Poisons Guidelines for the Conduct of Clinical Trials, 2022.

Kenya does not appear on the WHO maturity level 3 or 4 list as of the register's reference date. That is the absence of a published designation and nothing more. The framework is named, dated and specific.

Pakistan

Pakistan is neither an ICH member nor an observer, and applies ICH E6(R3) as national guidance. The authority is the Drug Regulatory Authority of Pakistan, under the DRAP Act 2012, section 7(c)(ix), with the Bio-Study Rules 2017, sections 3 and 7, and oversight by the Clinical Studies Committee.

The Clinical Studies Committee is worth noting specifically, because it is an oversight body a sponsor must engage with and whose existence a generic regional approach would miss entirely.

Argentina

Argentina is an ICH Regulatory Member. The authority is the Administración Nacional de Medicamentos, Alimentos y Tecnología Médica, and the governing instrument is Disposición ANMAT 6677/2010, the Régimen de Buena Práctica Clínica en Estudios de Farmacología Clínica.

Argentina does not appear on the WHO maturity level 3 or 4 list as of the register's reference date. Read that alongside its ICH Regulatory Membership and the point of this module becomes concrete: an ICH Regulatory Member with no WHO designation, and a non-member with a precise national instrument, sit side by side in the same register. Neither fact predicts the other.

In practice

A sponsor is deciding where to place a study and a business case describes several of these countries as "emerging markets, higher regulatory risk, longer timelines."

The regulatory lead rewrites the section with the register in front of her. Two of the countries are ICH Regulatory Members. Three have named statutory instruments with specific sections cited. One has guidance that is explicitly compulsory. One has an oversight committee the business case does not mention. Two carry WHO benchmarking with defined product scopes.

The revised section says something different and more useful: these are countries with specific, knowable requirements, several of which are not satisfied by a generic dossier, and the timeline risk is concentrated in identifiable places rather than spread as a general discount.

That version supports a decision. The original supported only a prejudice.

What this looks like when it goes wrong

A sponsor submits to South Africa treating the national good clinical practice guidelines as advisory, on the reasoning that guidelines are guidance.

Compliance with those guidelines is compulsory. The submission is assessed against them as a binding requirement, and several places where the sponsor followed its global procedure instead become deficiencies rather than acceptable alternatives.

The error is a general one worth naming: the status of a document is a fact about that document in that jurisdiction, not an inference from what it is called. "Guideline" is a word, not a status.

Key takeaways